Cellular Uptake, Distribution, and Stability of 10-23 Deoxyribozymes

Johnson and Johnson Research Laboratories, Eveleigh, Australia.
Antisense and Nucleic Acid Drug Development 11/2002; 12(5):289-99. DOI: 10.1089/108729002761381276
Source: PubMed


The cellular uptake, intracellular distribution, and stability of 33-mer deoxyribozyme oligonucleotides (DNAzymes) were examined in several cell lines. PAGE analysis revealed that there was a weak association between the DNAzyme and DOTAP or Superfect transfection reagents at charge ratios that were minimally toxic to cultured cells. Cellular uptake was analyzed by cell fractionation of radiolabeled DNAzyme, by FACS, and by fluorescent microscopic analysis of FITC-labeled and TAMRA-labeled DNAzyme. Altering DNAzyme size and chemistry did not significantly affect uptake into cells. Inspection of paraformaldehyde-fixed cells by fluorescence microscopy revealed that DNAzyme was distributed primarily in punctate structures surrounding the nucleus and that substantial delivery to the nucleus was not observed up to 24 hours after initiation of transfection. Incubation in human serum or plasma demonstrated that a 3'-inversion modification greatly increased DNAzyme stability (t(1/2) approximately 22 hours) in comparison to the unmodified form (t(1/2) approximately 70 minute). The 3'-inversion-modified DNAzymes remained stable during cellular uptake, and catalytically active oligonucleotide could be extracted from the cells 24 hours posttransfection. In smooth muscle cell proliferation assay, the modified DNAzyme targeting the c-myc gene showed a much stronger inhibitory effect than did the unmodified version. The present study demonstrates that DNAzymes with a 3'-inversion are readily delivered into cultured cells and are functionally stable for several hours in serum and within cells.

Download full-text


Available from: Edward Saravolac, May 15, 2015
  • Source
    • "DNAzymes can be designed to cleave virtually any RNA target by selecting appropriate flanking sequences [32], [33]. The recognition domains provide specificity and binding energy, however, if the binding strength is too strong or too weak between the DNAzyme and the substrate this can be antagonistic to catalysis [34], [35], [36]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: DNAzymes are DNA molecules that can directly cleave cognate mRNA, and have been developed to silence gene expression for research and clinical purposes. The advantage of DNAzymes over ribozymes is that they are inexpensive to produce and exhibit good stability. The "10-23 DNA enzyme" is composed of a catalytic domain of 15 deoxynucleotides, flanked by two substrate-recognition domains of approximately eight nucleotides in each direction, which provides the complementary sequence required for specific binding to RNA substrates. However, these eight nucleotides might not afford sufficient binding energy to hold the RNA substrate along with the DNAzyme, which would interfere with the efficiency of the DNAzyme or cause side effects, such as the cleavage of non-cognate mRNAs. In this study, we inserted a nonpairing bulge at the 5' end of the "10-23 DNA enzyme" to enhance its efficiency and specificity. Different sizes of bulges were inserted at different positions in the 5' end of the DNAzyme. The non-matching bulge will avoid strong binding between the DNAzyme and target mRNA, which may interfere with the efficiency of the DNAzyme. Our novel DNAzyme constructs could efficiently silence the expression of target genes, proving a powerful tool for gene silencing. The results showed that the six oligo bulge was the most effective when the six oligo bulge was 12-15 bp away from the core catalytic domain.
    PLoS ONE 04/2011; 6(4):e18629. DOI:10.1371/journal.pone.0018629 · 3.23 Impact Factor
  • Source
    • "Moreover, some NPs are capable of interacting with and crossing mucosal surfaces, escaping endolysosomal compartments and sustaining the release of the nucleic acid payload within the cell (Alonso 2004; Basarkar and Singh 2007). Appropriate selection of the administration route is highly important in gene delivery, due to the short degradation time of nucleic acid constructs in cells and in blood (Kawabata et al. 1995; Dass et al. 2002). Selection of the administration route could influence the ultimate therapeutic effect of the delivered nucleic acids. "
    [Show abstract] [Hide abstract]
    ABSTRACT: While the systemic route of administration enables therapeutic genes to spread through the bloodstream and access target cells, it is a challenge to achieve this. Several studies demonstrate that systemic administration of therapeutic genes or other nucleic acid-based constructs such as siRNA to solid tumors as well as cancer metastases are better with nanoparticulate systems compared to administration of free (uncomplexed) nucleic acids. Nanoparticle-based nucleic acid delivery systems might be more pertinent, due to the several privileges in terms of enhanced tissue penetrability, improved cellular uptake and to a lesser extent, targeted gene delivery to the cells of interest provided targeting ligands are used. Systemic delivery of nanoplexes has already been reported with different nanoparticles containing DNA via various routes of administration. The goal of the present article is to review the current state of intravenous delivery of nanoparticles for gene therapy of cancer.
    Pharmazie 12/2010; 65(12):855-9. DOI:10.1691/ph.2010.0168 · 1.05 Impact Factor
  • Source
    • "The 34 mer, 10-23 class of deoxyribozymes, Dz13 and Scr (the scrambled sequence control for Dz13) oligonucleotides were synthesised and prepared according to established conditions [25]. DNAzyme (0.8 μM) was transfected with Fugene-6 liposomes (Roche Diagnostics, Sydney, Australia) in complete medium. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The DNA enzyme Dz13, targeted against the oncogene c-Jun, is capable of inhibiting various model tumours in mice albeit in ectopic models of neoplasia. In previous studies using orthotopic models of disease, the inhibitory effects of Dz13 on secondary growth was a direct result of growth inhibition at the primary lesion site. Thus, the direct and genuine effects on metastasis were not gauged. In this study, Dz13 was able to inhibit both locoregional and distal metastasis of tumour cells in mice, in studies where the primary tumours were unaffected due to the late and clinically-mimicking nature of treatment commencement. In addition, the effect of Dz13 against tumours has now been extended to encompass breast and prostate cancer. Dz13 upregulated the matrix metalloproteinase (MMP)-2 and MMP-9, and decreased expression of MT1-MMP (MMP-14) in cultured tumour cells. However, in sections of ectopic tumours treated with Dz13, both MMP-2 and MMP-9 were downregulated. Thus, not only is Dz13 able to inhibit tumour growth at the primary site, but also able to decrease the ability of neoplastic cells to metastasize. These findings further highlight the growing potential of Dz13 as an antineoplastic agent.
    Cancer Cell International 03/2010; 10(1):9. DOI:10.1186/1475-2867-10-9 · 2.77 Impact Factor
Show more